双特异性抗体在结直肠癌治疗中的临床应用进展
Progress in Clinical Application of Bispecific Antibodies in Colorectal Cancer Treatment
刘欣 1郑丽云 2楼立兰 3沈红璋 2曹戟 4潘红英5
作者信息
- 1. 浙江大学医学院附属邵逸夫医院,杭州 310013;浙江大学,杭州 310058
- 2. 浙江大学,杭州 310058;西湖大学医学院附属杭州市第一人民医院,杭州 310006
- 3. 西湖大学医学院附属杭州市第一人民医院,杭州 310006
- 4. 浙江大学,杭州 310058
- 5. 浙江大学医学院附属邵逸夫医院,杭州 310013
- 折叠
摘要
近10年来,结直肠癌(colorectal cancer,CRC)的发病率持续上升,给个人和社会带来了沉重的负担.尽管靶向及免疫治疗显著改善了 CRC患者的临床预后,但耐药性及免疫应答率低等问题阻碍了其整体治愈率的进一步提升.双特异性抗体(bispecific antibody,BsAb)通过双靶点的设计有可能解决耐药及免疫应答的问题,成为近年来研究的热点.本文系统综述了目前用于CRC治疗的几种BsAb主要类型,并分述了 BsAb的不同靶点及在CRC治疗中的临床应用进展.以期为后续用于CRC治疗的BsAb研究设计提供有益参考.
Abstract
The incidence of colorectal cancer(CRC)is increasing in the decade,which has caused a serious burden for the individual and society.Although the targeted therapy and immunotherapy has significantly improved the clinical prognosis of CRC patients,the problems of drug resistance and low immune response rate hinder its further development of overall cure rate.Bispecific antibody(BsAb)as a hot field recently,and the problems of drug resistance and low immune response might be solved through the design of double targets.In this paper,several main types of BsAb used for CRC treatment at present are systematically reviewed,the different targets of BsAb and its clinical application progress in CRC treatment are discussed.Trying to provide useful reference for the subsequent research and design of BsAb for CRC treatment.
关键词
双特异性抗体/结直肠癌/临床应用Key words
bispecific antibody/colorectal cancer/clinical application引用本文复制引用
出版年
2024
NETL
NSTL
万方数据